PMID: 1591689Jun 15, 1992Paper

Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients

Cancer
N A PavlidisG Petroutsos

Abstract

The current study has prospectively investigated the incidence and course of ocular toxicity after low-dose tamoxifen treatment. Sixty-three patients with cancer who could be examined were analyzed. Tamoxifen was administered on a 20-mg daily dose. Median duration of treatment was 25 months. Median total tamoxifen dose was 14.4 gr. Four patients had retinopathy and/or keratopathy 10, 27, 31, and 35 months, respectively, after tamoxifen initiation (an incidence of 6.3%). Ophthalmologic findings consisted of decreased visual acuity, bilateral macular edema, yellow-white dots in the paramacular and fovea areas in all patients as well as corneal opacities in one patient. After tamoxifen withdrawal almost all ocular abnormalities were found to be reversible, except for the retinal opacities. This is the first prospective study in the literature indicating that even conventional low-dose tamoxifen treatment can induce ocular toxicity. In addition, the authors review and discuss the literature of the last decades.

References

Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T J PowlesJ A McKinna
Nov 1, 1989·Survey of Ophthalmology·P S ImperiaJ H Lass
Aug 15, 1987·American Journal of Ophthalmology·M F Griffiths
Jan 1, 1988·Cancer·A R AshfordT J Garrett
Jul 15, 1986·Cancer·T Pugesgaard, F E Von Eyben
Feb 1, 1983·Acta Ophthalmologica·T Vinding, N V Nielsen
Mar 1, 1981·The British Journal of Ophthalmology·C A McKeownJ M Maggiano
Jan 1, 1981·Ophthalmology·M I Kaiser-KupferM M Rodrigues

❮ Previous
Next ❯

Citations

Oct 1, 1996·Cancer·T al-TweigeriJ R Mackey
Jan 1, 1995·Journal of Cellular Biochemistry. Supplement·J Russo, I H Russo
Jul 1, 1993·Stem Cells·V G Jordan, M Morrow
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·A U BuzdarI H Krakoff
Jan 1, 1994·Breast Cancer Research and Treatment·T J PowlesM Baum
Nov 17, 2009·Documenta Ophthalmologica. Advances in Ophthalmology·Sung Eun Song WatanabeSolange Rios Salomão
Sep 20, 2006·International Ophthalmology·Brendan G CroninRobert D Bourke
May 4, 2013·Drugs·Olga E MakriConstantine D Georgakopoulos
Jul 1, 1995·Journal of Hepatology·H C PintoM C de Moura
Aug 25, 2004·Survey of Ophthalmology·Paris G TranosCarlos E Pavesio
Apr 29, 1998·American Journal of Ophthalmology·M B GorinD Kaufmann
Oct 31, 2000·Ophthalmology·C J FlaxelZ J Gregor
Oct 2, 1998·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·J C Chang
Sep 21, 2004·Breast Cancer Research and Treatment·Brian D BradburySusan S Jick
Mar 9, 2000·Eye·B N NoureddinA Khalil
Jan 4, 2007·Assay and Drug Development Technologies·Maria E Verdugo-GazdikMark W Tengowski
Jan 1, 1996·Obstetrical & Gynecological Survey·V L Baker, R B Jaffe
Jul 13, 2000·Obstetrical & Gynecological Survey·V L BakerR B Jaffe
Dec 9, 2004·Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society·Mohammad AbdollahiShekoufeh Nikfar
Aug 19, 2006·Anti-cancer Drugs·Chien-Liang LiuTsang-Pai Liu
Sep 16, 2006·Eye & Contact Lens·Orkun MuftuogluAyfer Kanpolat
May 14, 2010·Menopause : the Journal of the North American Menopause Society·Daniel María Lubian LópezRafael Comino Delgado
Aug 1, 1995·British Journal of Pharmacology·J J ZhangM A Valverde
Jan 29, 1993·Science·B E HendersonM C Pike
Aug 1, 2002·Drugs & Aging·Michael S SimonMiron Stano
Jun 26, 2002·Proceedings of the National Academy of Sciences of the United States of America·Vicki L DavisKenneth S Korach
Dec 24, 2010·Acta Veterinaria Scandinavica·Wanessa L F TavaresGeovanni D Cassali
Jul 19, 2012·Expert Opinion on Drug Metabolism & Toxicology·Mitan R GokulgandhiAshim K Mitra
Jan 20, 2015·Cutaneous and Ocular Toxicology·Marilita M MoschosGeorge Zografos
Aug 9, 2011·Current Eye Research·Alvin Eisner, Shiuh-Wen Luoh
Jan 1, 1995·Cancer Investigation·D V SpicerM C Pike
Apr 25, 2007·Current Eye Research·Solange Rios SalomãoMarcia Motono
Apr 1, 2014·Cutaneous and Ocular Toxicology·Seyda UgurluMeryem Altin Ekin
Dec 9, 2010·The American Journal of the Medical Sciences·Preston H Blomquist
Nov 7, 1992·Lancet·A Fugh-Berman, S Epstein
Mar 4, 2014·American Journal of Ophthalmology·Rishi R DoshiPhilip J Rosenfeld
Jan 1, 1997·Journal of Obstetric, Gynecologic, and Neonatal Nursing : JOGNN·V A McKeon

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.